Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Hopes New Data Will Expand Boundaries Of DES Population

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific expects the new data from two trials released at the Transcatheter Cardiovascular Therapeutics Scientific Symposium in Washington, D.C., last week will encourage physicians to reconsider drug-eluting stents for a broader range of patients
Advertisement

Related Content

New Products In Brief
American College Of Cardiology Conference In Brief
American College Of Cardiology Conference In Brief
Long-Term AHRQ/ACC Data Support Drug-Eluting Stent Safety In Elderly
Long-Term AHRQ/ACC Data Support Drug-Eluting Stent Safety In Elderly
Drug-Eluting Stents Perform Well In An Emergency, NEJM Data Shows
Drug-Eluting Stents Perform Well In An Emergency, NEJM Data Shows
CABG Beats DES In SYNTAX Trial; Observers Expect Little Change In Practice
Advertisement
UsernamePublicRestriction

Register

MT026686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel